Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.Race is pursuing outsized commercial returns for shareholders via its ‘Three Pillar' strategy for the clinical development of Zantrene.

Website: raceoncology.com

Employees: 5 - 9

HQ: N/A

Location: Melbourne, VIC, AU

Revenue: Not Available

Looking for contact information for Race Oncology? ConnectPlex is the answer. ConnectPlex.ai is a cutting-edge B2B lead generation platform that provides accurate and up-to-date contact information for millions of companies worldwide, including Race Oncology. Our AI-powered algorithms ensure that our data is always current and accurate, so you can be sure that you're getting the most reliable information possible. Whether you're looking to partner with Race Oncology or get in touch with their team, ConnectPlex is the perfect place to start your search. At ConnectPlex, we understand the importance of having access to the right contact information. That's why we've developed a user-friendly platform that makes it easy to find and connect with the people you need to reach. With our platform, you can quickly and easily find contact information for Race Oncology and other companies in the oncology industry. Start your search today and see the difference that ConnectPlex can make for your business.

Race Oncology is a precision oncology company based in Melbourne, Australia, focused on developing innovative cancer therapies. The company's lead drug candidate, Zantrene, is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein, which is overexpressed in a diverse range of cancers. Race is currently exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, as well as investigating its use in other cancer types such as Acute Myeloid Leukaemia (AML), breast, and ovarian cancers. Race Oncology's 'Three Pillar' strategy for the clinical development of Zantrene aims to deliver outsized commercial returns for shareholders. The company's management team includes experienced executives with a strong track record in the pharmaceutical industry, including Chief Scientific Officer (CSO) & Executive Director Daniel Tillett, CEO & Managing Director Phillip Lynch, and Managing Director John Cullity. With a strong focus on innovation and a commitment to delivering new cancer therapies to market, Race Oncology is poised to make a significant impact in the fight against cancer.

Race Oncology is a company that is listed on the Australian stock exchange. They are working on a drug called Zantrene, which is in the second stage of testing and could potentially treat different types of cancer. Zantrene works by blocking a protein called FTO, which is involved in many types of cancer. The company is looking at using Zantrene to treat two specific types of cancer: melanoma and clear cell renal cell carcinoma. They also have evidence that another drug, Bisantrene, may be useful in treating other types of cancer, such as leukemia, breast cancer, and ovarian cancer, and are exploring its potential in these areas. The company's goal is to make a lot of money for its shareholders by developing Zantrene in a way that is unique and effective.